Virological rebound after suppression on highly active antiretroviral therapy
- 1 August 2003
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 17 (12) , 1741-1751
- https://doi.org/10.1097/00002030-200308150-00003
Abstract
Objective: To determine the rate of virological rebound and factors associated with rebound among patients on highly active antiretroviral therapy (HAART) with previously undetectable levels of viraemia. Design: An observational cohort study of 2444 patients from the EuroSIDA study. Methods: Patients were followed from their first viral load under 400 copies/ml to the first of two consecutive viral loads above 400 copies/ml. Incidence rates were calculated using person-years of follow-up (PYFU), Cox proportional hazards models were used to determine factors related to rebound. Results: Of 2444 patients, 1031 experienced virological rebound (42.2%). The incidence of rebound decreased over time; from 33.5 in the first 6 months after initial suppression to 8.6 per 100 PYFU at 2 years after initial suppression (P <0.0001). The rate of rebound was lower for treatment-naive compared with treatment-experienced patients. In multivariate models, patients who changed treatment were more likely to rebound, as were patients with higher viral loads on starting HAART. Treatment-naive patients were less likely to rebound. Among pretreated patients, those who were started on new nucleosides were less likely to rebound. Conclusion: The rate of virological rebound decreased over time, suggesting that the greatest risk of treatment failure is in the months after initial suppression. Treatment-naive patients were at a lower risk of rebound, but among drug-experienced patients, those who added new nucleosides had a lower risk of rebound, as were patients with a good immunological response. (C) 2003 Lippincott Williams & WilkinKeywords
This publication has 36 references indexed in Scilit:
- Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic populationAIDS, 2000
- Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in EuropeArchives of internal medicine (1960), 2000
- Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitorAIDS, 2000
- Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug ReactionsAnnals of Internal Medicine, 1999
- Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapyAIDS, 1999
- HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapyAIDS, 1999
- Outcome and Predictors of Failure of Highly Active Antiretroviral Therapy: One‐Year Follow‐Up of a Cohort of Human Immunodeficiency Virus Type 1–Infected PersonsThe Journal of Infectious Diseases, 1999
- Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort studyThe Lancet, 1999
- Virological response to protease inhibitor therapy in an HIV clinic cohortAIDS, 1999
- Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patientsAIDS, 1997